

Recent patent applications in RNA interference

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
WO 2009103808	A method for increasing an RNA interference (RNAi) effect of a molecule or composition by contacting the cell(s) or organism with sulfated polysaccharides and/or glycosaminoglycans and an RNAi-inducing molecule.	deVGen (Zwijnaarde, Belgium)	Philips A, Raemaekers R	2/20/2008	8/27/2009
WO 2009083738	A new RNA delivery vehicle comprising a clostridial neurotoxin translocation peptide, useful for delivering an RNA guide strand into a target cell and suppressing or downregulating gene expression by RNAi in a target cell.	Syntaxin (Abingdon, UK)	Beard M, Chaddock J	12/31/2007	7/9/2009, 8/27/2009
WO 2009102931, US 20090209627	A method for treating an intraocular pressure-related condition in an individual comprising administering an interfering RNA molecule that attenuates expression of the connexin 43 (Cx43) mRNA via RNAi.	Alcon Research (Fort Worth, TX, USA)	Chatterton JE, Clark AF, Wax MB	2/15/2008	8/20/2009
US 20090192105	A new chemically modified nucleic acid molecule, useful for modulating intercellular adhesion molecule (ICAM) gene expression, and providing compositions for treating diseases and conditions that respond to ICAM modulation (e.g., cancer).	Sirna Therapeutics (San Francisco)	Beigelman L, McSwiggen J	2/20/2002	7/30/2009
US 20090192104	A new chemically modified nucleic acid molecule, useful for modulating hypoxia inducible factor (HIF), and modulating expression and activity of other genes involved in pathways of <i>HIF1</i> gene expression and/or activity by RNAi.	Sirna Therapeutics (San Francisco)	Beigelman L, McSwiggen J	2/20/2002	7/30/2009
WO 2009088786	A method of treating heart failure comprising administering to an individual a vector comprising an RNAi expression cassette to decrease expression or activity of phospholamban.	Nanacor Therapeutics (Chapel Hill, NC, USA)	Fechner H, Hajjar RJ, Poller WC	12/31/2007	7/16/2009
US 20090181913	A novel specific 78-kDa glucose-regulated protein (GRP78) expression-inhibition RNAi used for inhibiting growth, metastasis and invasion of cancer cells.	Chang JT, Cheng A, Chiu C	Chang JT, Cheng A, Chiu C	1/11/2008	7/16/2009
WO 2009082488	A method of producing a hairpin DNA molecule comprising a loop and a substantially double-stranded stem by fragmenting a cDNA, enzymatically ligating and enzymatically digesting the intermediate DNA molecule with an endonuclease.	BergenBio (Bergen, Norway)	Lorens J, Micklem D	12/24/2007	7/2/2009
US 20090156536	An isolated small interfering RNA molecule comprising a sense region and an antisense region that downregulates expression of a genetic disruption of p38 (AIMP2)-DX2 gene via RNAi.	Kim S	Choi JW, Kim S	11/24/2004	6/18/2009
WO 2009073809	A new RNAi agent for modulating the expression of a target gene in treating, e.g., cancer, hepatitis C, dyslipidemia, diabetes, childhood asthma, malaria and multiple sclerosis, comprising a small interfering molecule conjugated to a carbohydrate.	Alnylam Pharmaceuticals (Cambridge, MA, USA)	Maier M, Manoharan M, Narayanannair JK, Rajeev KG	12/4/2007	6/11/2009
CN 101455848	Selecting a tumor metastasis-inhibiting gene using an RNAi library, comprising injecting a cell treated by RNAi into an immunodeficient mouse to form a lung tumor and expressing the tumor metastasis-inhibiting gene.	Huang H	Huang H, Luo R	6/17/2009	1/5/2009
US 20060247428, JP 2008283975	A method for synthesizing a double-stranded nucleic acid molecule, comprising a sense strand and an antisense strand by annealing two complementary strands under conditions suitable to obtain a double-stranded nucleic acid molecule.	Ribozyme Pharmaceuticals (Boulder, CO, USA), Sirna Therapeutics (San Francisco)	Beigelman L, Chen T, Chowrira B, Fosnaugh K, Haeberli P, Jamison S, Macejak D, McSwiggen J, Mokler V, Morrissey D, Pavco P, Thompson J, Usman N, Vaish N, Vargeese C, Wang W, Zinnen S	2/20/2002	11/2/2006, 11/27/2008

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (<http://www.thomson.com/scientific>).

